PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-2.92%
Negative revenue growth while AVGO stands at 0.59%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-2.87%
Negative gross profit growth while AVGO is at 0.51%. Joel Greenblatt would examine cost competitiveness or demand decline.
-1.68%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-1.68%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-2.71%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-3.18%
Share reduction while AVGO is at 0.26%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-3.45%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
25.02%
Dividend growth above 1.5x AVGO's 0.14%. David Dodd would verify if the firm's cash flow is robust enough for these payouts.
-7.05%
Negative OCF growth while AVGO is at 7.23%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-9.93%
Negative FCF growth while AVGO is at 6.62%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
66.42%
10Y revenue/share CAGR under 50% of AVGO's 409.54%. Michael Burry would suspect a lasting competitive disadvantage.
96.86%
5Y revenue/share CAGR at 75-90% of AVGO's 122.61%. Bill Ackman would encourage strategies to match competitor’s pace.
41.72%
3Y revenue/share CAGR at 50-75% of AVGO's 60.90%. Martin Whitman would question if the firm lags behind competitor innovations.
241.13%
10Y OCF/share CAGR at 50-75% of AVGO's 441.92%. Martin Whitman might fear a structural deficiency in operational efficiency.
127.23%
5Y OCF/share CAGR above 1.5x AVGO's 73.80%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
37.02%
3Y OCF/share CAGR similar to AVGO's 34.25%. Walter Schloss might see both benefiting from a rising tide or parallel expansions.
401.02%
Net income/share CAGR at 50-75% of AVGO's 691.11%. Martin Whitman might question if the firm’s product or cost base lags behind.
252.29%
Below 50% of AVGO's 651.30%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
93.61%
3Y net income/share CAGR 1.25-1.5x AVGO's 66.58%. Bruce Berkowitz might see new markets, M&A, or better cost discipline driving the difference.
91.65%
Below 50% of AVGO's 839.21%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
10.40%
Below 50% of AVGO's 147.32%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
-4.05%
Negative 3Y equity/share growth while AVGO is at 188.08%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
361.20%
Below 50% of AVGO's 1441.93%. Michael Burry might see weaker long-term distribution growth, raising questions about the firm's capital allocation.
355.42%
5Y dividend/share CAGR above 1.5x AVGO's 71.80%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.
294.10%
3Y dividend/share CAGR above 1.5x AVGO's 38.29%. David Dodd sees a superior short-term capital return strategy if supported by stable earnings.
-13.89%
Firm’s AR is declining while AVGO shows 14.59%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-2.21%
Inventory is declining while AVGO stands at 5.71%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-7.70%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-7.50%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
No Data
No Data available this quarter, please select a different quarter.
-6.09%
Our R&D shrinks while AVGO invests at 19.53%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-1.63%
We cut SG&A while AVGO invests at 14.12%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.